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Abstract A single chain Fv fragment (scFv) of the murine 
monoclonal antibody 11-1G10 was constructed by directly 
joining the C-terminal residue of the V H domain to the N-
terminal residue of VL . 11-1G10 is an anti-idiotype and competes 
with the antigen, influenza virus neuraminidase (NA), for binding 
to the NC41 antibody. The scFv formed stable trimers with three 
active antigen combining sites for NC41 Fab fragments. We 
propose that trimeric scFvs may be the preferred conformation 
for directly linked V R - V L molecules, which contrasts the 
formation of scFv dimers (diabodies) when the V H and VL 
domains are joined by short flexible linkers of between 5-10 
residues. BIAcore biosensor binding experiments showed that the 
trimeric scFv showed an expected increase in binding affinity, 
due to avidity, compared to the monomeric 15-residue linked 
scFv. The increase in avidity of scFv trimers offers advantages 
for imaging and immunotherapy. 
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1. Introduction 
Recombinant single chain variable fragments (scFvs), in 
which the two variable domains are covalently joined via a 
flexible peptide linker, have been shown to fold in the same 
conformation as the parent Fab [1,2]. ScFvs with linkers 
greater than 12 residues in length can form stable monomers 
which usually exhibit similar antigen binding affinity com-
pared to the parent antibody [1,3]. Reduction of the linker 
length to shorter than 12 residues prevents the monomeric 
configuration and forces two scFv molecules into a dimeric 
conformation, termed diabodies [4-6]. The increased tumour 
to blood ratio reported for these bivalent scFv dimers over 
monomers [7], presumably from higher avidity and reduced 
clearance rates, offers advantages for imaging, diagnosis and 
therapy. Bispecific diabodies have been produced using bicis-
tronic vectors to express two different scFv molecules in situ, 
VHA-linker-VLB and VHB-linker-VLA, which associate to 
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form the parent specificities of A and B [5,8,9]. The 5 residue 
linker sequence chosen for these bispecific diabodies, Gly4Ser, 
provided a flexible and hydrophilic hinge. 
ScFv molecules have been designed without a linker (scFv-
0), by direct ligation of the C-terminal residue of V H to the N-
terminal residue of VL [4,10]. Although these scFv-0 structures 
have been modelled as dimers with V H domains joined back-
to-back [4], the structure is severely constrained and cannot be 
accommodated in the crystal structure of a 5-residue linked 
dimeric scFv [11]. In contrast, we have recently demonstrated 
that an scFv-0 derived from antibody NC10, specific for in-
fluenza virus neuraminidase (NA), was a trimer with three 
active antigen combining sites [12]. We initially thought that 
this trimeric conformation was unique to NC10 scFv, perhaps 
due to steric clashes between V-domains which prevented the 
dimeric association. However, we show in this report that a 
second scFv, constructed from the anti-idiotype 11-1G10 anti-
body, is also a trimer and also possesses trivalent specificity. 
The parent antibody, murine 11-1G10 competes for binding 
to the murine NC41 antibody with the original target antigen, 
influenza virus N9 neuraminidase (NA) [13]. We now propose 
that the propensity to trimerise might be a general property of 
scFv-0 molecules constructed by direct ligation of V H - V L do-
mains. 
2. Materials and methods 
2.1. Construction of 1I-1G10 scFv-0 
The VH and VL genes were amplified by PCR from the parent 11-
1G10 hybridoma [P. Iliades, in preparation], and joined into an scFv-
0 gene by ligation between codons for C-terminal Vn-Ser113 and N-
terminal VL-Gln1 by PCR overlap-extension. Residues are numbered 
according to the Kabat nomenclature as described [1]. The scFv-0 
gene was cloned into the Sfi\-Nof[ sites of the expression vector 
pGC using methods described previously [14]. The vector pGC pro-
vides an N-terminal pelB leader sequence and C-terminal FLAG oc-
tapeptide tag tail [14]. The entire DNA sequence of the cloned scFv-0 
insert was determined using DNA purified by alkaline lysis and se-
quencing reactions performed using the PRISM Cycle Sequencing Kit 
(ABI). 
2.2. Expression and purification of 11-1G10 scFv and NC41 Fab 
fragments 
HB101 E. coli containing the scFv-0 gene in pGC were grown in 
2XYT supplemented with 100 ug/ml ampicillin and 1% glucose at 
37°C overnight and then subcultured in the absence of glucose at 
an Agoo of 0.1, and grown at 21°C until Aeoo was 1.0. Expression 
was induced by addition of IPTG to 1 mM and cells cultured for 
16 h at 21°C. Cells and culture supernatant were separated by cen-
trifugation and samples of cell pellet and supernatant were analysed 
on a 15% SDS-PAGE gel followed by Western blot analysis using M2 
anti-FLAG antibody [15] and goat anti mouse IgG (H+L)IIRP (Bio-
Rad) as the second antibody to visualise the expressed product. 
The expressed scFv-0 was purified from supernatant by precipita-
tion with ammonium sulphate to 70% saturation at 21°C followed by 
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Fig. 1. SDS-PAGE analysis of scFv-15 and scFv-0 and Western Transfer detection using anti-FLAG M2 antibody; lanes on Coomassie stained 
gel (a) Biorad Low Mr standards, (b) scFv-0, (c) scFv-15 and corresponding Western blot of (d) scFv-0 and (e) scFv-15. The theoretical Mr of 
scFv-15 is 28427 Da and scFv-0 is 26466 Da. 
centrifugation at lOOOOXg for 15 min. The aqueous phase was dis-
carded, and the pellet resuspended and dialysed in PBS (phosphate-
buffered saline, pH 7.4) at 4°C overnight. Insoluble material was 
removed by centrifugation at 70 000 X g and the supernatant was fil-
tered through a 0.22 |xm membrane and affinity purified on either an 
M2 anti-FLAG antibody affinity column [15] or an NC41 Fab Se-
pharose 4B affinity column. The affinity resin was equilibrated in TBS 
(0.025 M Tris-buffered saline, pH 7.4) and bound protein was eluted 
with gentle elution buffer (Pierce). The scFv-0 was concentrated to 
~ 1 mg/ml, dialysed against TBS and stored at 4°C. SDS-PAGE, 
Western Blot analysis and N-terminal sequence analysis of the affinity 
purified material were performed as described previously [1]. 
For the other proteins described in this study, 11-1G10 scFv-15 
(comprising a 15 residue linker in the orientation VH-(Gly4Ser)3-VL) 
was synthesised under similar conditions to the scFv-0 described 
above [P. Iliades, in preparation]. The 11-1G10 scFv-15 was isolated 
by gel filtration as a 27-kDa monomer and shown to be stable at 4°C 
for several weeks, similar to previous studies with different scFv-15 
fragments [1-6,12]. NC41 and 11-1G10 Fab fragments were prepared 
by proteolysis from the parent hybridoma IgG as described previously 
[12,16]. 
2.3. Size exclusion FPLC chromatography, molecular mass 
determination and binding analysis 
The affinity purified scFv-0 and scFv-15 was fractionated by size 
exclusion FPLC on either a Superdex 75 HR10/30 column or a Super-
ose 12 HR 10/30 column (Pharmacia) in PBS to determine the molec-
ular size and aggregation state. The complexes formed between 11-
1G10 scFv and NC41 Fab were analysed and isolated by size exclu-
sion FPLC on a Superose 12 column in PBS (flow rate 0.5 ml/min). 
The FPLC columns were calibrated with standard proteins as de-
scribed [1]. The molecular mass of each isolated complex was deter-
mined by sedimentation equilibrium on a Beckman model XLA cen-
trifuge as described previously [1,12] using partial specific volumes 
calculated from amino acid compositions. An upgraded Pharmacia 
BIAcore 1000 was used for analysis of the binding of monomeric 
11-1G10 scFv-15 and trimeric 11-1G10 scFv-0 to immobilised NC41 
Fab as described [12,17]. The resulting binding curves were analysed 
with BIAevaluation 2.1 software (Pharmacia Biosensor), to obtain 
values for the apparent dissociation rate constants [17]. 
3. Results 
D N A sequencing confirmed that the 11-1G10 scFv-0 gene 
comprised a direct ligation between codons for the C-terminal 
Vn-Ser113 and N-terminal VL-Gln1. Expression of the scFv-0 
gene was performed in E. coli strain HB101 for 16 h at 21°C 
under conditions which release the contents of the periplasmic 
space into the culture supernatant, presumably by cell lysis, to 
yield soluble and biologically active scFv [14]. 
3.1. ScFv purification and solution properties 
Fully active scFv-0 was purified at 0.5 mg/L from the cul-
ture supernatant by affinity chromatography on an NC41 
Fab-Sepharose affinity column. SDS-PAGE analysis of the 
affinity purified scFv-0 revealed a single protein band of 27 
k D a which on Western analysis reacted with the an t i -FLAG 
M 2 antibody (Fig. 1). N-terminal sequence analysis of the 27-
Table 1 
Sedimentation equilibrium data for complexes of 11-1G10 scFv-15 
monomer and scFv-0 trimer with NC41 Fab 
Sample 
Monomer+NC41 Fab 
28427+47273 
Trimer 
Trimer+NC41 Fab 
79398+141819 
Calculated 
75700 
79398 
221217 
Experimental 
78600 
85 000 
262000 
The complexes of NC41 Fab with either scFv-15 monomer or scFv-0 
trimer were isolated by size exclusion FPLC chromatography and 
analysed by sedimentation equilibrium in a Beckman Model XLA 
ultracentrifuge. The molecular mass was determined experimentally 
by the method described in [12] at 20°C. The calculated Mr of 
NC41 Fab is 47 273 Da, scFv-15 is 28427 Da, and scFv-0 is 26466 
Da. 
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Fig. 2. Size exclusion FPLC on a calibrated Superdex 75 HRlO/30 column (Pharmacia) showing overlayed profiles of scFv-15 monomer and 
scFv-0 trimer with peaks eluting at times corresponding to Mt ~27 kDa and ~85 kDa, respectively. The column was equilibrated with PBS 
(pH 7.4) and run at a flow rate of 0.5 ml/min. 
kDa protein gave the expected sequence for the N terminus of 
the 11-1G10 VH domain and confirmed that the pelB leader 
sequence had been correctly cleaved (data not shown). 
Gel filtration of affinity purified scFv by FPLC on either a 
Superdex 75 column (Fig. 2) or a Superose 12 column (Fig. 3) 
revealed a single peak of Mr ~ 8 5 kDa consistent with the 
calculated molecular mass of a trimer (calculated Mv 79.2 
kDa). Gel filtration of the scFv-0 preparation showed no evi-
dence of monomers and dimers and no evidence of proteolytic 
degradation to single V-domains. Sedimentation equilibrium 
analysis indicated that the scFv-0 migrated as a distinct spe-
cies with MT ~ 8 5 kDa (Table 1) consistent with a trimeric 
conformation and there was no evidence for a dimeric spe-
cies which might exist in rapid equilibrium with the trimer 
species. 
In comparison, the scFv-15 fragment of 11-1G10 (compris-
ing a 15 residue linker in the orientation VH-(Gly4Ser)3-VL) 
was also synthesised using the pGC vector in HB2151 E. coli 
cells and then purified as a stable monomer with a MT ~ 2 7 
kDa determined by gel filtration and sedimentation equilib-
rium (Figs. 1 and 2). Previous gel filtration and sedimenta-
tion equilibrium studies of NC10 scFv fragments [12] had 
revealed that scFv-15 monomers possessed an Mr ~ 2 7 
kDa, scFv-5 dimers Mv ~ 5 4 kDa and scFv-0 trimers Mr 
~ 7 0 kDa [12]. Thus, the calculated and experimental Mx of 
~ 2 7 kDa for monomeric scFv-15 derived from both 11-1G10 
10 
4 -
Complex 11-1G10 Trimer 
NC41 Fab 
16 20 22 24 26 28 30 
Time (min) 
Fig. 3. Size exclusion FPLC on a calibrated Superose 12 HRlO/30 column (Pharmacia) showing overlayed profiles of the isolated 11-1G10 
scFv-0 trimer, NC41 Fab and scFv/Fab complex formed on the interaction of scFv-0 and NC41 Fab premixed in 1:3 molar ratio. The column 
was equilibrated with PBS (pH 7.4) and run at a flow rate of 0.5 ml/min. 
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Fig. 4. BIAcore sensorgrams showing the association and dissocia-
tion of scFv-15 monomer and scFv-0 trimer each at a concentration 
of 222 nM, to immobilised NC41 Fab. An injection volume of 30 
ul and a flow rate of 5 ul/min were used. The surface was regener-
ated with 10 ul of 10 mM sodium acetate, pH 3.0 after each bind-
ing experiment. 
and NC10 antibodies were almost identical, whereas scFv-0 
from 11-1G10 exhibited a Mr ~ 8 5 kDa slightly larger than 
that predicted for a trimer (79 kDa) and scFv-0 from NC10 a 
MT ~ 70 kDa slightly smaller than a trimer. 
3.2. Interaction between 11-1-G10 scFv and NC41 Fab 
fragments 
Gel filtration analysis by FPLC on a Superose 12 column 
showed that all the scFv-0 interacted with NC41 Fab to form 
a stable complex of MT ~245 kDa (Fig. 3) whilst scFv-15 
monomer interacted with NC41 Fab to form a stable complex 
of Mr ~ 79 kDa (not shown). The molecular mass of these 
complexes were determined by sedimentation equilibrium 
analysis to be 262 kDa and 78.6 kDa, respectively (Table 1). 
The linearity of the In c versus r2 plots [12] of the sedimenta-
tion data showed that both complexes were homogeneous 
with respect to molecular mass and indicated that discrete 
and stoichiometric complexes were formed. Furthermore, 
both isolated complexes were stable to dilution, and freezing 
(data not shown). These data are consistent with the trimeric 
scFv-0 binding three Fab molecules whilst the monomeric 
scFv-15 formed a 1:1 complex with Fab. Comparison of the 
binding of scFv-15 monomer and scFv-0 trimer to immobi-
lised NC41 Fab by BIAcore (Fig. 4) showed that the apparent 
dissociation rate of the scFv-0 trimer/ NC41 Fab complex 
(&d~8.2xl0~5 s_1) was approximately 4-fold slower than 
that for the scFv-15 monomer/NC41 Fab complex 
(&d~3 .2x l0 - 4 s_1). These dissociation rates are only ap-
proximate values since the sensorgram analysis required a 
1:1 interaction model [17]. The 4-fold reduced apparent dis-
sociation rate for the 11-1G10 scFv-0 trimer is similar to our 
previous analysis on the NC10 scFv-0 trimer [12] and can be 
attributed to multivalent binding which results in the in-
creased avidity for both scFv-0 trimers. 
4. Discussion 
Linkers less than 12 residues are too short to permit pairing 
between VH and VL domains on the same chain and have been 
used to force an intermolecular pairing of domains into 
dimers, termed diabodies [4,6,11,12]. However, in only a few 
studies [11,12] have accurate molecular mass analyses for 
scFvs with shorter linkers been reported. Holliger et al. [4,5] 
described a model of scFv diabodies with VH domains joined 
back-to-back and suggested these structures required a linker 
of at least one or two residues. This model was confirmed in a 
crystal structure of a 5-residue diabody [11], but it was noted 
that scFv-0 could not be fitted to this conformation, even with 
severe rotations of the VH domains. Desplancq et al. [18] 
described a series of scFvs with linkers of 10, 5 and zero 
residues and showed by FPLC analysis that these scFvs 
were predominantly dimers with minor amounts of monomer. 
Alfthan et al. [19] also showed that scFvs with a small linkers 
down to 2 residues in length formed dimers. McGuinness et 
al. [10] claimed that bispecific scFv-0 molecules were diabodies 
and could be displayed and selected from bacteriophage libra-
ries, but precise molecular size determination was not per-
formed on the expressed soluble products. 
We have recently reported that scFv-5 and scFv-10 mole-
cules derived from an NC10 antibody (with 5 and 10 residues 
linking the VH and VL domains, respectively) formed stable 
dimers, but that the NC10 scFv-0 formed a stable trimer [12]. 
In the design of the trimeric NC10 scFv-0 residues Ser112 and 
Asp1 were ligated as a direct fusion of VH-VL domains and, 
presumably, the absence of a flexible linker prevents the di-
meric configuration [12]. The C-terminal residue Ser112 was 
chosen from precise structural data, obtained by crystallo-
graphic analysis [20], as the last constrained residue in the 
VH domain framework before the start of the flexible hinge 
region. Similarly, Asp1 of VL was known to be hydrogen 
bonded to the V-domain framework and was close, but not 
involved, in antigen binding. The NC10 scFv molecules were 
fully active since the scFv-5 and scFv-10 were bivalent and 
scFv-0 was trivalent. In contrast, Holliger et al. [4] provided 
an additional linker residue (Vn-Ser113) which might have 
provided the additional flexibility required for their diabody 
conformation. 
For the design of 11-1G10 scFv-0 we included, like Holliger 
et al. [4], an additional residue VH-Ser113 for the direct ligation 
to VL-Gln1. The 11-1G10 scFv-0 exclusively formed trimers 
(Fig. 2), which were shown to be fully active and trivalent for 
Fab binding by complex formation in solution (Fig. 3). In 
contrast, the 11-1G10 scFv-15 preferentially formed mono-
mers with a small percentage of dimers, consistent with 
most previous observations of scFv-15 structures [1-6]. The 
slight difference between calculated and experimental molec-
ular masses determined by gel filtration and sedimentation 
equilibrium is within the usual error range for these analytical 
methods (Table 1). As expected, binding experiments with the 
immobilised NC41 Fab on the BIAcore biosensor showed that 
the trimer had a slower dissociation rate compared to the 
monomer and can be attributed to the increased avidity of 
multivalent binding (Fig. 4). 
ScFv-0 molecules can be easily modelled into a symmetric 
P. Iliades et al.lFEBS Letters 409 (1997) 437^141 441 
trimeric conformation without interdomain steric constraints 
[12]. In this model of NC10 scFv-0, and in preliminary elec-
tron micrograph images (P. Tulloch, unpublished), the F a b 
arms of the tr imer/Fab complex are not extended in planar 
configuration, but are angled together in one direction and 
appear as the legs of a tripod. Obviously, alternative config-
urations can be modelled, guided by steric constraints which 
limit both the flexibility of Fv modules and the proximity of 
three binding antigens. Unfortunately, protein chemical da ta 
alone cannot differentiate between symmetric or non-symmet-
ric trimer configurations. 
It is tempting to speculate that the trimeric conformation 
(triabodies) will be preferred over dimers (diabodies) for other 
scFv-0 molecules, al though this property may be dependent 
on the particular antibody chosen and the precise choice of 
residues for the VH-ViTinkage. The gain in affinity through 
avidity makes trimeric scFvs attractive for in vivo imaging 
as an alternative reagent to diabodies [7] and multivalent 
chemical conjugates [21-24]. It is also tempting to speculate 
that the increased avidity and tumour penetration of these 
small multivalent scFv molecules will offer advantages for 
immunotherapy [21-25]. Furthermore, the construction of tri-
cistronic expression vectors should enable the production of 
trispecific scFv-0 reagents with applications in cell recruitment 
and activation. The flexibility of trimers is unknown and may 
limit their ability to cross-link two cells via their surface re-
ceptors. 
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